Intratus

Intratus is a clinical-stage biotech company pioneering novel transdermal drug delivery systems with an initial focus on ophthalmology. Its platform aims to provide sustained, targeted drug release with potentially greater efficacy and fewer adverse events compared to traditional methods. Founded in 2005, the company remains private and is leveraging its intellectual property portfolio to develop and monetize internal R&D assets. With operational capacity spanning the U.S., Europe, Asia, and South America, Intratus seeks to cause a paradigm shift in how medications are delivered to patients.

Patented, non-invasive, sustained-release transdermal drug delivery platform designed for optimized, targeted tissue delivery with potential for improved efficacy and reduced adverse events.

Intratus competes in the innovative ophthalmic drug delivery space against companies developing sustained-release implants, punctal plugs, and other novel formulations. Its differentiation hinges on the success of its specific transdermal approach in achieving effective and patient-friendly delivery.